Mis on psühhedeelikumid?

Kirjandus

Aday, J. S., Mitzkovitz, C. M., Bloesch, E. K., Davoli, C. C., & Davis, A. K. (2020). Long-term effects of psychedelic drugs: A systematic review. Neuroscience and Biobehavioral Reviews, 113(March), 179–189. https://doi.org/10.1016/j.neubiorev.2020.03.017

Andersson, M., Persson, M., & Kjellgren, A. (2017). Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. Harm Reduction Journal. https://doi.org/10.1186/s12954-017-0186-6

Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). Emotions and brain function are altered up to one month after a single high dose of psilocybin. Scientific Reports. https://doi.org/10.1038/s41598-020-59282-y

Barrett, F. S., & Griffiths, R. R. (2018). Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. In Current Topics in Behavioral Neurosciences. https://doi.org/10.1007/7854_2017_474

Becker, A. M., Klaiber, A., Holze, F., Istampoulouoglou, I., Duthaler, U., Varghese, N., Eckert, A., & Liechti, M. E. (2023). Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants. The International Journal of Neuropsychopharmacology. https://doi.org/10.1093/ijnp/pyac075

Belser, A. B., Agin-Liebes, G., Swift, T. C., Terrana, S., Devenot, N., Friedman, H. L., Guss, J., Bossis, A., & Ross, S. (2017). Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Journal of Humanistic Psychology. https://doi.org/10.1177/0022167817706884

Bentall, R. P. (1990). The Illusion of Reality: A Review and Integration of Psychological Research on Hallucinations. Psychological Bulletin. https://doi.org/10.1037/0033-2909.107.1.82

Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology. https://doi.org/10.1177/0269881114565144

Bouso, J. C., Andión, Ó., Sarris, J. J., Scheidegger, M., Tófoli, L. F., Opaleye, E. S., Schubert, V., & Perkins, D. (2022). Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. PLOS Global Public Health. https://doi.org/10.1371/journal.pgph.0000438

Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015). Long-term use of psychedelic drugs is associated with differences in brain structure and personality in humans. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2015.01.008

Buot, A., Pallares, C., Oganesyan, A., Dauré, C., Bonnelle, V., Burguière, E., Dos Santos, J. F. A., N’diaye, K., Ljuslin, M., Smith, P., & others. (2023). Improvement in OCD symptoms associated with serotoninergic psychedelics: a retrospective online survey. Scientific Reports, 13(1), 13378.

Burmester, D. R., Madsen, M. K., Szabo, A., Aripaka, S. S., Stenbæk, D. S., Frokjaer, V. G., Elfving, B., Mikkelsen, J. D., Knudsen, G. M., & Fisher, P. M. D. (2023). Subacute effects of a single dose of psilocybin on biomarkers of inflammation in healthy humans: An open-label preliminary investigation. Comprehensive Psychoneuroendocrinology. https://doi.org/10.1016/j.cpnec.2022.100163

Calder, A. E., & Hasler, G. (2023). Towards an understanding of psychedelic-induced neuroplasticity. In Neuropsychopharmacology. https://doi.org/10.1038/s41386-022-01389-z

Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116662634

Carbonaro, T. M., Johnson, M. W., Hurwitz, E., & Griffiths, R. R. (2018). Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. Psychopharmacology. https://doi.org/10.1007/s00213-017-4769-4

Carhart-Harris, R. L. (2018). The entropic brain - revisited. In Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2018.03.010

Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Psychopharmacology. https://doi.org/10.1007/s00213-017-4771-x

Carhart-Harris, R. L., & Goodwin, G. M. (2017). The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. Neuropsychopharmacology. https://doi.org/10.1038/npp.2017.84

Close, J. B., Hajien, E. C., Watts, R., Roseman, L., & Carhart-Harris, R. L. (2020). Psychedelics and psychological flexibility – Results of a prospective web-survey using the Acceptance and Action Questionnaire II. Journal of Contextual Behavioral Science. https://doi.org/10.1016/j.jcbs.2020.01.005

Davis, A. K., Barrett, F. S., & Griffiths, R. R. (2020). Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. Journal of Contextual Behavioral Science. https://doi.org/10.1016/j.jcbs.2019.11.004

Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021). Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.3285

de Vos, C. M. H., Mason, N. L., & Kuypers, K. P. C. (2021). Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. In Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2021.724606

Doss, M. K., Považan, M., Rosenberg, M. D., Sepeda, N. D., Davis, A. K., Finan, P. H., Smith, G. S., Pekar, J. J., Barker, P. B., Griffiths, R. R., & Barrett, F. S. (2021). Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Translational Psychiatry. https://doi.org/10.1038/s41398-021-01706-y

Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart-Harris, R. L. (2018). Effects of psilocybin therapy on personality structure. Acta Psychiatrica Scandinavica. https://doi.org/10.1111/acps.12904

Erritzoe, David, Smith, J., Fisher, P. M., Carhart-Harris, R., Frokjaer, V. G., & Knudsen, G. M. (2019). Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. Journal of Psychopharmacology. https://doi.org/10.1177/0269881119827891

Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023). The psychedelic afterglow phenomenon: a systematic review of subacute effects of classic serotonergic psychedelics. Therapeutic Advances in Psychopharmacology. https://doi.org/10.1177/20451253231172254

Flanagan, T. W., Billac, G. B., Landry, A. N., Sebastian, M. N., Cormier, S. A., & Nichols, C. D. (2021). Structure-Activity Relationship Analysis of Psychedelics in a Rat Model of Asthma Reveals the Anti-Inflammatory Pharmacophore. ACS Pharmacology and Translational Science. https://doi.org/10.1021/acsptsci.0c00063

Flanagan, T. W., Sebastian, M. N., Battaglia, D. M., Foster, T. P., Cormier, S. A., & Nichols, C. D. (2019). 5-HT2 receptor activation alleviates airway inflammation and structural remodeling in a chronic mouse asthma model. Life Sciences. https://doi.org/10.1016/j.lfs.2019.116790

Forstmann, M., & Sagioglou, C. (2017). Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117714049

Fysh, R. R., Oon, M. C. H., Robinson, K. N., Smith, R. N., White, P. C., & Whitehouse, M. J. (1985). A fatal poisoning with LSD. Forensic Science International. https://doi.org/10.1016/0379-0738(85)90067-2

Gandy, S., Bonnelle, V., Jacobs, E., & Luke, D. (2022). Psychedelics as potential catalysts of scientific creativity and insight. Drug Science, Policy and Law. https://doi.org/10.1177/20503245221097649

Garcia-Romeu, A., Darcy, S., Jackson, H., White, T., & Rosenberg, P. (2022). Psychedelics as Novel Therapeutics in Alzheimer’s Disease: Rationale and Potential Mechanisms. In Current Topics in Behavioral Neurosciences. https://doi.org/10.1007/7854_2021_267

Garcia-Romeu, A., Davis, A. K., Erowid, E., Erowid, F., Griffiths, R. R., & Johnson, M. W. (2020). Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2019.00955

Garcia-Romeu, A., Davis, A. K., Erowid, F., Erowid, E., Griffiths, R. R., & Johnson, M. W. (2019). Cessation and reduction in alcohol consumption and misuse after psychedelic use. Journal of Psychopharmacology. https://doi.org/10.1177/0269881119845793

Garcia-Romeu, A., Griffiths, R. R., & Johnson, M. W. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. Current Drug Abuse Reviews. https://doi.org/10.2174/1874473708666150107121331

Gashi, L., Sandberg, S., & Pedersen, W. (2021). Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences. International Journal of Drug Policy, 87, 102997. https://doi.org/10.1016/j.drugpo.2020.102997

Gasser, P., Kirchner, K., & Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: A qualitative study of acute and sustained subjective effects. Journal of Psychopharmacology. https://doi.org/10.1177/0269881114555249

Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., Burke, L., Campbell-Coker, K., Carhart-Harris, R., Cattell, J., Daniel, A., DeBattista, C., Dunlop, B. W., Eisen, K., Feifel, D., … Malievskaia, E. (2022). Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2206443

Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A., Stoll, M., Stock, C., Obradovic, M., & Kovar, K. A. (2005). Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. https://doi.org/10.1055/s-2005-916185

Grieco, S. F., Castrén, E., Knudsen, G. M., Kwan, A. C., Olson, D. E., Zuo, Y., Holmes, T. C., & Xu, X. (2022). Psychedelics and Neural Plasticity: Therapeutic Implications. Journal of Neuroscience. https://doi.org/10.1523/JNEUROSCI.1121-22.2022

Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116675513

Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. Psychopharmacology. https://doi.org/10.1007/s00213-011-2358-5

Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632. https://doi.org/10.1177/0269881108094300

Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology. https://doi.org/10.1007/s00213-006-0457-5

Griggs, E. A., & Ward, M. (1977). LSD toxicity. A suspected cause of death. Journal of the Kentucky Medical Association.

Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstad, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Archives of General Psychiatry. https://doi.org/10.1001/archgenpsychiatry.2010.116

Grob, C. S., McKenna, D. J., Callaway, J. C., Brito, G. S., Neves, E. S., Oberlaender, G., Saide, O. L., Labigalini, E., Tacla, C., Miranda, C. T., Strassman, R. J., & Boone, K. B. (1996). Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. Journal of Nervous and Mental Disease. https://doi.org/10.1097/00005053-199602000-00004

Haden, M., & Woods, B. (2020). LSD overdoses: Three case reports. Journal of Studies on Alcohol and Drugs. https://doi.org/10.15288/jsad.2020.81.115

Haeny, A. M., Lopez, J. A., Colón Grigas, P. A., Crouch, M. C., Davis, A. K., & Williams, M. (2023). Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada. Journal of Substance Use and Addiction Treatment. https://doi.org/10.1016/j.josat.2023.209035

Hanks, J. B., & González-Maeso, J. (2016). Molecular and Cellular Basis of Hallucinogen Action. In Neuropathology of Drug Addictions and Substance Misuse Volume 2: Stimulants, Club and Dissociative Drugs, Hallucinogens, Steroids, Inhalants and International Aspects. https://doi.org/10.1016/B978-0-12-800212-4.00075-3

Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004). Acute psychological and physiological affects of psilocybin in healthy humans: A double-blind, placebo-controlled dose-effect study. Psychopharmacology, 172(2), 145–156. https://doi.org/10.1007/s00213-003-1640-6

Healy, C. J. (2021). The acute effects of classic psychedelics on memory in humans. In Psychopharmacology. https://doi.org/10.1007/s00213-020-05756-w

Heekeren, K., Neukirch, A., Daumann, J., Stoll, M., Obradovic, M., Kovar, K. A., Geyer, M. A., & Gouzoulis-Mayfrank, E. (2007). Prepulse inhibition of the startle reflex and its attentional modulation in the human S-ketamine and N,N-dimethyltryptamine (DMT) models of psychosis. Journal of Psychopharmacology. https://doi.org/10.1177/0269881107077734

Holze, F., Caluori, T. V., Vizeli, P., & Liechti, M. E. (2021). Safety pharmacology of acute LSD administration in healthy subjects. Psychopharmacology. https://doi.org/10.1007/s00213-021-05978-6

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., & Kuypers, K. P. C. (2019). Self-Rated Effectiveness of Microdosing With Psychedelics for Mental and Physical Health Problems Among Microdosers. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2019.00672

Hutten, N. R. P. W., Mason, N. L., Dolder, P. C., Theunissen, E. L., Holze, F., Liechti, M. E., Varghese, N., Eckert, A., Feilding, A., Ramaekers, J. G., & Kuypers, K. P. C. (2021). Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. ACS Pharmacology and Translational Science. https://doi.org/10.1021/acsptsci.0c00099

Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology. https://doi.org/10.1177/0269881114548296

Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019). Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. In Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2018.11.010

Kaup, K. K., Vasser, M., Tulver, K., Pikamäe, J., & Aru, J. (2023). Psychedelic replications in virtual reality and their potential as a therapeutic instrument: An open-label feasibility study. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1088896

Kelmendi, B., Kichuk, S. A., DePalmer, G., Maloney, G., Ching, T. H. W., Belser, A., & Pittenger, C. (2022). Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report. Heliyon. https://doi.org/10.1016/j.heliyon.2022.e12135

Kettner, H., Gandy, S., Haijen, E. C. H. M., & Carhart-Harris, R. L. (2019). From egoism to ecoism: Psychedelics increase nature relatedness in a state-mediated and context- dependent manner. International Journal of Environmental Research and Public Health, 16(24). https://doi.org/10.3390/ijerph16245147

Köck, P., Froelich, K., Walter, M., Lang, U., & Dürsteler, K. M. (2022). A systematic literature review of clinical trials and therapeutic applications of ibogaine. Journal of Substance Abuse Treatment. https://doi.org/10.1016/j.jsat.2021.108717

Kometer, M., Schmidt, A., Jäncke, L., & Vollenweider, F. X. (2013). Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations. Journal of Neuroscience, 33(25), 10544–10551. https://doi.org/10.1523/JNEUROSCI.3007-12.2013

Kometer, M., & Vollenweider, F. X. (2018). Serotonergic hallucinogen-induced visual perceptual alterations. In Current Topics in Behavioral Neurosciences. https://doi.org/10.1007/7854_2016_461

Kozlowska, U., Nichols, C., Wiatr, K., & Figiel, M. (2022). From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders. In Journal of Neurochemistry. https://doi.org/10.1111/jnc.15509

Kwan, A. C., Olson, D. E., Preller, K. H., & Roth, B. L. (2022). The neural basis of psychedelic action. In Nature Neuroscience. https://doi.org/10.1038/s41593-022-01177-4

Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping, 37(9), 3203–3213. https://doi.org/10.1002/hbm.23234

Lepow, L., Morishita, H., & Yehuda, R. (2021). Critical Period Plasticity as a Framework for Psychedelic-Assisted Psychotherapy. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2021.710004

Leptourgos, P., Fortier-Davy, M., Carhart-Harris, R., Corlett, P. R., Dupuis, D., Halberstadt, A. L., Kometer, M., Kozakova, E., LarØi, F., Noorani, T. N., Preller, K. H., Waters, F., Zaytseva, Y., & Jardri, R. (2020). Hallucinations under Psychedelics and in the Schizophrenia Spectrum: An Interdisciplinary and Multiscale Comparison. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaa117

Letheby, C. (2021). Philosophy of Psychedelics. In Philosophy of Psychedelics. https://doi.org/10.1093/med/9780198843122.001.0001

Ley, L., Holze, F., Arikci, D., Becker, A. M., Straumann, I., Klaiber, A., Coviello, F., Dierbach, S., Thomann, J., Duthaler, U., Luethi, D., Varghese, N., Eckert, A., & Liechti, M. E. (2023). Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01607-2

Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics Promote Structural and Functional Neural Plasticity. Cell Reports. https://doi.org/10.1016/j.celrep.2018.05.022

MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. Journal of Psychopharmacology. https://doi.org/10.1177/0269881111420188

Madsen, Martin K., Fisher, P. M., Burmester, D., Dyssegaard, A., Stenbæk, D. S., Kristiansen, S., Johansen, S. S., Lehel, S., Linnet, K., Svarer, C., Erritzoe, D., Ozenne, B., & Knudsen, G. M. (2019). Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology, 44(7), 1328–1334. https://doi.org/10.1038/s41386-019-0324-9

Madsen, Martin Korsbak, Fisher, P. M. D., Stenbæk, D. S., Kristiansen, S., Burmester, D., Lehel, S., Páleníček, T., Kuchař, M., Svarer, C., Ozenne, B., & Knudsen, G. M. (2020). A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2020.02.001

Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of Psychopharmacology, 29(3), 241–253. https://doi.org/10.1177/0269881114568040

Mason, N. L., Mischler, E., Uthaug, M. V., & Kuypers, K. P. C. (2019). Sub-Acute Effects of Psilocybin on Empathy, Creative Thinking, and Subjective Well-Being. Journal of Psychoactive Drugs, 51(2), 123–134. https://doi.org/10.1080/02791072.2019.1580804

Masters, R. E. L., & Houston, J. (1966). The Varietes of psychedelic experience (1st ed.). Dell Publishing.

Milliere, R. (2020). Varieties of Selflessness. Philosophy and the Mind Sciences, 1(I), 1–41. https://doi.org/10.33735/phimisci.2020.i.48

Millière, R. (2017). Looking for the self: Phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. Frontiers in Human Neuroscience, 11(May), 1–22. https://doi.org/10.3389/fnhum.2017.00245

Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., … Doblin, R. (2021). MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine. https://doi.org/10.1038/s41591-021-01336-3

Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., Kuutti, M., Fred, S. M., Elsilä, L. V., Sakson, S., Cannarozzo, C., Diniz, C. R. A. F., Seiffert, N., Rubiolo, A., Haapaniemi, H., … Castrén, E. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience. https://doi.org/10.1038/s41593-023-01316-5

Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. Journal of Clinical Psychiatry. https://doi.org/10.4088/JCP.v67n1110

Nardou, R., Lewis, E. M., Rothhaas, R., Xu, R., Yang, A., Boyden, E., & Dölen, G. (2019). Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature. https://doi.org/10.1038/s41586-019-1075-9

Nardou, R., Sawyer, E., Song, Y. J., Wilkinson, M., Padovan-Hernandez, Y., de Deus, J. L., Wright, N., Lama, C., Faltin, S., Goff, L. A., Stein-O’Brien, G. L., & Dölen, G. (2023). Psychedelics reopen the social reward learning critical period. Nature. https://doi.org/10.1038/s41586-023-06204-3

Nayak, S. M., & Griffiths, R. R. (2022). A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities. Frontiers in Psychology, 13(March), 1–8. https://doi.org/10.3389/fpsyg.2022.852248

Nayak, S. M., Singh, M., Yaden, D. B., & Griffiths, R. R. (2023). Belief changes associated with psychedelic use. Journal of Psychopharmacology. https://doi.org/10.1177/02698811221131989

Netzband, N., Ruffell, S., Linton, S., Tsang, W. F., & Wolff, T. (2020). Modulatory effects of ayahuasca on personality structure in a traditional framework. Psychopharmacology. https://doi.org/10.1007/s00213-020-05601-0

Nichols, D. E. (2004). Hallucinogens. Pharmacology & Therapeutics, 101(2), 131–181.

Nichols, D. E. (2016). Psychedelics. Pharmacological Reviews. https://doi.org/10.1124/pr.115.011478

Nichols, D. E., & Grob, C. S. (2018). Is LSD toxic? In Forensic Science International. https://doi.org/10.1016/j.forsciint.2018.01.006

Nikayin, S., Murphy, E., Krystal, J. H., & Wilkinson, S. T. (2022). Long-term safety of ketamine and esketamine in treatment of depression. In Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2022.2066651

Nikolaidis, A., Lancelotta, R., Gukasyan, N., Griffiths, R. R., Barrett, F. S., & Davis, A. K. (2023). Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2022.12.042

Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017). Psychedelics, Personality and Political Perspectives. Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2017.1312643

Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016). Ego-dissolution and psychedelics: Validation of the ego-dissolution inventory (EDI). Frontiers in Human Neuroscience. https://doi.org/10.3389/fnhum.2016.00269

Nutt, D. J., King, L. A., & Phillips, L. D. (2010). Drug harms in the UK: A multicriteria decision analysis. The Lancet. https://doi.org/10.1016/S0140-6736(10)61462-6

Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418–434.

Palhano-Fontes, F., Barreto, D., Onias, H., Andrade, K. C., Novaes, M. M., Pessoa, J. A., Mota-Rolim, S. A., Osório, F. L., Sanches, R., Dos Santos, R. G., Tófoli, L. F., De Oliveira Silveira, G., Yonamine, M., Riba, J., Santos, F. R., Silva-Junior, A. A., Alchieri, J. C., Galvão-Coelho, N. L., Lobão-Soares, B., … Araújo, D. B. (2019). Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: A randomized placebo-controlled trial. Psychological Medicine. https://doi.org/10.1017/S0033291718001356

Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience and Therapeutics, 14(4), 295–314. https://doi.org/10.1111/j.1755-5949.2008.00059.x

Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. In Addiction Biology. https://doi.org/10.1080/1355621021000005937

Pöllänen, E., Osika, W., Stenfors, C. U. D., & Simonsson, O. (2022). Classic Psychedelics and Human–Animal Relations. International Journal of Environmental Research and Public Health. https://doi.org/10.3390/ijerph19138114

Preller, K. H., & Vollenweider, F. X. (2018). Phenomenology, structure, and dynamic of psychedelic states. In Current Topics in Behavioral Neurosciences. https://doi.org/10.1007/7854_2016_459

Quednow, B. B., Kometer, M., Geyer, M. A., & Vollenweider, F. X. (2012). Psilocybin-induced deficits in automatic and controlled inhibition are attenuated by ketanserin in healthy human volunteers. Neuropsychopharmacology, 37(3), 630–640. https://doi.org/10.1038/npp.2011.228

Raison, C. L., Sanacora, G., Woolley, J., Heinzerling, K., Dunlop, B. W., Brown, R. T., Kakar, R., Hassman, M., Trivedi, R. P., Robison, R., & others. (2023). Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial. JAMA.

Raval, N. R., Johansen, A., Donovan, L. L., Ros, N. F., Ozenne, B., Hansen, H. D., & Knudsen, G. M. (2021). A single dose of psilocybin increases synaptic density and decreases 5-HT2A receptor density in the pig brain. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms22020835

Ravimiamet. (2023). Kliinilised Uuringud Ravimiamet. https://www.ravimiamet.ee/ravimid-ja-ohutus/ravimiuuringud/kliinilised-uuringud#ravimiuuringute-faas

Richards, W. A. (2016). Sacred Knowledge: Psychedelics and Religious Experiences. Columbia University Press. http://www.jstor.org/stable/10.7312/rich17406

Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., & Schmidt, B. L. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology. https://doi.org/10.1177/0269881116675512

Ruck, C. A., Bigwood, J., Staples, D., Ott, J., & Wasson, R. G. (1979). Entheogens. Journal of Psychedelic Drugs, 11(1–2), 145–146.

Rudin, D., Areesanan, A., Liechti, M. E., & Gründemann, C. (2023). Classic psychedelics do not affect T cell and monocyte immune responses. Frontiers in Psychiatry. https://doi.org/10.3389/fpsyt.2023.1042440

Saeger, H. N., & Olson, D. E. (2022). Psychedelic-inspired approaches for treating neurodegenerative disorders. In Journal of Neurochemistry. https://doi.org/10.1111/jnc.15544

Sagioglou, C., & Forstmann, M. (2022). Psychedelic use predicts objective knowledge about climate change via increases in nature relatedness. Drug Science, Policy and Law. https://doi.org/10.1177/20503245221129803

Schep, L. J., Slaughter, R. J., Galea, S., & Newcombe, D. (2016). Ibogaine for treating drug dependence. What is a safe dose? In Drug and Alcohol Dependence. https://doi.org/10.1016/j.drugalcdep.2016.07.005

Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H., Luddy, C., Flynn, L. T., Lindsey, H., Pittman, B. P., Cozzi, N. V., & D’Souza, D. C. (2021). Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin. Neurotherapeutics, 18(1), 534–543. https://doi.org/10.1007/s13311-020-00962-y

Schlag, A. K., Aday, J., Salam, I., Neill, J. C., & Nutt, D. J. (2022). Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 36(3), 258–272. https://doi.org/10.1177/02698811211069100

Schmid, Y., Enzler, F., Gasser, P., Grouzmann, E., Preller, K. H., Vollenweider, F. X., Brenneisen, R., Müller, F., Borgwardt, S., & Liechti, M. E. (2015). Acute effects of lysergic acid diethylamide in healthy subjects. Biological Psychiatry, 78(8), 544–553. https://doi.org/10.1016/j.biopsych.2014.11.015

Schneier, F. R., Feusner, J., Wheaton, M. G., Gomez, G. J., Cornejo, G., Naraindas, A. M., & Hellerstein, D. J. (2023). Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2023.03.031

Sessa, B. (2005). Can psychedelics have a role in psychiatry once again? In British Journal of Psychiatry. https://doi.org/10.1192/bjp.186.6.457

Simonsson, O., Hendricks, P. S., Chambers, R., Osika, W., & Goldberg, S. B. (2023). Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2023.01.073

Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F., & Carhart-Harris, R. (2021). Psychedelics alter metaphysical beliefs. https://doi.org/https://doi.org/10.31234/osf.io/f6sjk

Torrado Pacheco, A., Olson, R. J., Garza, G., & Moghaddam, B. (2023). Acute psilocybin enhances cognitive flexibility in rats. Neuropsychopharmacology. https://doi.org/10.1038/s41386-023-01545-z

United Nations. (1972). The Single Convention on Narcotic Drugs, 1961, As amended by the 1972 Protocol. In United Nations.

Uthaug, M. V., van Oorsouw, K., Kuypers, K. P. C., van Boxtel, M., Broers, N. J., Mason, N. L., Toennes, S. W., Riba, J., & Ramaekers, J. G. (2018). Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology. https://doi.org/10.1007/s00213-018-4988-3

Uthaug, Malin V., Lancelotta, R., Szabo, A., Davis, A. K., Riba, J., & Ramaekers, J. G. (2020). Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology. https://doi.org/10.1007/s00213-019-05414-w

van Elk, M., & Yaden, D. B. (2022). Pharmacological, neural, and psychological mechanisms underlying psychedelics: A critical review. In Neuroscience and Biobehavioral Reviews. https://doi.org/10.1016/j.neubiorev.2022.104793

Vann Jones, S. A., & O’Kelly, A. (2020). Psychedelics as a Treatment for Alzheimer’s Disease Dementia. In Frontiers in Synaptic Neuroscience. https://doi.org/10.3389/fnsyn.2020.00034

Vizeli, P., & Liechti, M. E. (2017). Safety pharmacology of acute MDMA administration in healthy subjects. Journal of Psychopharmacology. https://doi.org/10.1177/0269881117691569

Vogt, S. B., Ley, L., Erne, L., Straumann, I., Becker, A. M., Klaiber, A., Holze, F., Vandersmissen, A., Mueller, L., Duthaler, U., Rudin, D., Luethi, D., Varghese, N., Eckert, A., & Liechti, M. E. (2023). Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants. Translational Psychiatry. https://doi.org/10.1038/s41398-023-02477-4

Vollenweider, F. X., & Smallridge, J. W. (2022). Classic Psychedelic Drugs: Update on Biological Mechanisms. In Pharmacopsychiatry. https://doi.org/10.1055/a-1721-2914

Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998). Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. NeuroReport. https://doi.org/10.1097/00001756-199812010-00024

Watts, R., Day, C., Krzanowski, J., Nutt, D., & Carhart-Harris, R. (2017). Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Journal of Humanistic Psychology. https://doi.org/10.1177/0022167817709585

Wießner, I., Olivieri, R., Falchi, M., Palhano-Fontes, F., Oliveira Maia, L., Feilding, A., B. Araujo, D., Ribeiro, S., & Tófoli, L. F. (2022). LSD, afterglow and hangover: Increased episodic memory and verbal fluency, decreased cognitive flexibility. European Neuropsychopharmacology. https://doi.org/10.1016/j.euroneuro.2022.01.114